Actively Recruiting
The Efficacy of Doxycycline Post Exposure Prophylaxis for Preventing STIs Among MSM in Bangkok, Thailand.
Led by Bangrak STIs Center · Updated on 2026-02-09
400
Participants Needed
1
Research Sites
86 weeks
Total Duration
On this page
Sponsors
B
Bangrak STIs Center
Lead Sponsor
M
Mahidol University
Collaborating Sponsor
AI-Summary
What this Trial Is About
The objective of this research is to evaluate the efficacy and safety of doxycycline in MSM for preventing sexually transmitted infections (gonorrhea, chlamydia, and syphilis) in Thailand Participation in this study will last approximately 12 weeks and will include 2-3 clinic visits, along with 10-11 follow-up phone contacts over a period of 11 weeks.
CONDITIONS
Official Title
The Efficacy of Doxycycline Post Exposure Prophylaxis for Preventing STIs Among MSM in Bangkok, Thailand.
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Biological male, aged 18 years or older and not over 60 years
- Thai nationality
- Able to read, communicate, and understand the Thai language
- Men who have sex with men
- History of condomless sex or condom failure with at least two sexual partners within the past 3 months
- Diagnosis of gonorrhea, chlamydia, or syphilis within the past 6 months
- Current use of HIV pre-exposure prophylaxis (PrEP)
- Willing and able to participate in study procedures, including returning for scheduled testing and completing doxycycline use records
- Willing and able to provide written informed consent
You will not qualify if you...
- Allergy to tetracycline-class antibiotics
- Untreated syphilis or currently receiving treatment with benzathine penicillin G or doxycycline
- Received benzathine penicillin G within the past 12 weeks
- Prior receipt of a gonorrhea vaccine
- Current use of medications that may interact with doxycycline, including vitamin A derivatives, antiepileptic drugs, immunosuppressive agents, heart failure or arrhythmia medications, anticoagulants, or blood cell-affecting medications
- History of renal impairment (eGFR < 60 mL/min/1.73 m2) or hepatic impairment (AST or ALT > 3 times upper limit)
- Uncontrolled or unstable underlying diseases such as hematologic disorders, cancer, autoimmune diseases, or neurological disorders
- Severe medical or psychiatric conditions that increase study-related risk or impair consent ability
- Alcohol or illicit drug dependence within the past 12 months affecting doxycycline use
- Previous participation in this study with prior randomization
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Bangrak STIs Center
Sathorn, Bangkok, Thailand, 10120
Actively Recruiting
Research Team
R
Rossapnorn Kittiyaowamarn, MD
CONTACT
K
Kittipoom Chinhiran, MD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
PREVENTION
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here